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p73 cooperates with Ras in the activation of MAP
kinase signaling cascade
B Fernandez-Garcia1, JP Vaque´2, M Herreros-Villanueva1, F Marques-Garcia1, F Castrillo1, A Fernandez-Medarde3, J Leo´n2
and MC Marı´n*,1
The p73 gene is capable of inducing cell cycle arrest, apoptosis, senescence, differentiation and to cooperate with oncogenic
Ras in cellular transformation. Ras can be considered as a branch point in signal transduction, where diverse extracellular
stimuli converge. The intensity of the mitogen-activated protein kinase (MAPK) cascade activation influences the cellular
response to Ras. Despite the fundamental role of p53 in Ras-induced growth arrest and senescence, it remains unclear how the
Ras/MEK/ERK pathway induces growth arrest in the absence of p53. We report here that oncogenic Ras stabilizes p73 resulting
in p73 accumulation and enhancement of its activity. p73, in turn, induces a sustained activation of the MAP kinase cascade
synergizing with oncogenic Ras. We also found that inhibition of p73 function modifies the cellular outcome to Ras activation
inhibiting Ras-dependent differentiation. Here, we show for the first time that there is a signaling loop between Ras-dependent
MAPK cascade activation and p73 function.
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The p53 family members, p73 and p63, share significant
sequence homology with p53, but unlike p53, they give raise
to multiple protein isoforms owing to alternative mRNA
splicing and promoter utilization.1 Increase in TAp73a
expression correlates with certain differentiation processes
and has tumor suppression functions,2 whereas DNp73a can
cooperate with oncogenic Ras in cellular transformation.3 The
cellular outcome of p73 upregulation is dependent on the
cellular context, but the full nature of this regulation remains
unknown.4
Ras proteins were originally identified through their
cell transformation properties, but since then they have
been shown to regulate divergent functions such as
cell proliferation, differentiation and apoptosis. The orchestra-
tion of a variety of signaling pathways to produce diverse
and specific cellular outcomes requires the ability of Ras
to activate a particular responsive module for each
specific stimulus.5 Upon external stimuli, Ras becomes
transiently activated relaying its signal to downstream
effectors. The signaling intensity by the Raf/MEK/
ERK module is known to play an important role in Ras-
induced cell cycle arrest and cellular differentiation.6 In
rat pheochromocytoma PC12 cells, sustained activation
of extracellular signal-regulated kinase (ERK) is required for
neuronal differentiation, whereas transient activation
of ERK leads to increased proliferation.6 This scenario
requires crosstalk between the contextual modulators and
the mitogen-activated protein kinase (MAPK) cascade com-
ponents.
The functional interaction between some of the pathways
engaged by oncogenic Ras and the growth suppression
function of p53 is well established.7,8 However, despite the
fundamental role of p53 in Ras-induced growth arrest and
senescence, p53-independent pathways for Ras outcomes
have also been described. Ras-mediated growth arrest and
p21WAF1 upregulation has been reported in p53-deficient
cells.9 These observations suggest the existence of Ras-
induced pathways leading to growth arrest, senescence and
differentiation which are independent of p53.
In contrast to the previous avenue of data on the Ras-p53
crosstalk, there is little or no information about a possible Ras-
p73 functional interaction. The capacity of p73 of inducing
apoptosis, senescence, differentiation or transformation,3,10
makes the p73 gene a suitable candidate to be a modulator of
Ras cellular outcome.
Here, we report for the first time, that there is a signaling
loop between Ras-dependent MAPK cascade activation and
p73 function.
Results
Constitutively active Ras induces p73 accumulation. To
investigate a possible Ras-p73 crosstalk, we took advantage
of the Ras-inducible UR61 model.11 This is a PC12-derived
cell line which contains a stably integrated transforming
mouse N-ras(Lysine-61) gene under the control of a
dexamethasone (Dex)-inducible promoter.
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Treatment with Dex resulted in an increase in p73 protein,
reaching maximal levels at 12 h (Figure 1a and Supplemen-
tary Figure 1a and b). To identify the specific p73 isoform
expressed, we run in vitro translated proteins corresponding
to the isoforms TAp73a, TAp73b and DNp73a. We found that
TAp73a was the predominant isoform induced by activated
Ras in this cell line (Figure 1a and Supplementary Figure 1a).
Although UR61 cells expressed detectable basal levels of p63
and p53 under standard culture conditions (Supplementary
Figure 1a), an increase in the expression was not detected
upon Ras induction neither by RT-PCR (Figure 1b) nor by
immunoblot (Supplementary Figure 1a). This observation
suggests that they may not play a role in Ras-induced
differentiation in this cellular model.
The increased level of p73 in the presence of Ras was not
due to enhanced p73 transcription, as Ras did not affect the
levels of p73 RNA (Figure 1b). Furthermore, in transcriptional
assays using the p73-P1-promoter-luciferase as a reporter,
transfected H-RasV12 or induced N-RasK61 failed to stimu-
late p73-P1 luciferase activity, whereas ectopic E2F1 could
activate this promoter (Figure 1c).
The former results are coherent with a post-transcriptional
mechanism of Ras-mediated p73 accumulation. To elucidate
the mechanism by which Ras augments p73 levels, we
Figure 1 Constitutive active Ras stabilizes TAp73a. Oncogenic ras induces accumulation of p73. (a) Immunoprecipitation/Western blot analysis showed upregulation of
endogenous TAp73 following treatment of UR61 cells with dexamethasone (Dex). At the indicated time points, cell lysates were prepared and equal amount of protein was
immunoprecipitated with anti-p73 antibody (ER15) and analyzed by Western blot. Equivalent amounts of input sample was run along and levels of induced N-RasK61 was
analyzed by Western blot with an specific anti-N-Ras antibody. Total ERK expression was assessed as loading control. In vitro translated protein corresponding to the TAp73a
isoform was run along the samples. Activated Ras induces accumulation of p73 by a post-transcriptional mechanism. (b) Expression of different p53 family members was
analyzed in Dex-treated UR61 cells by semiquantitative RT-PCR. (c) Transcriptional analysis of the P1-p73 promoter-luciferase reporter in UR61 cells in the presence or
absence of Dex, transfected with increasing amounts of H-Ras V12 (0.5–2mg) or 2 mg of E2F. Luciferase activity was normalized by the Renilla activity of the same lysate. The
data represent the mean of at least three experiments. Error bars indicate S.E. Ras overexpression increases p73 at steady-state levels. (d) UR61 and (e) SH-SY-5Y cells
were transiently transfected with empty vector, HA-TAp73a or HA-p53 alone or together with constitutive active Ras (H-Ras V12). Equal amount of GFP expression vector was
cotransfected with each sample. Cell lysates were prepared 24 h after transfection and equal amounts of protein were loaded. GFP expression was assessed as loading and
transfection efficiency control. Oncogenic Ras prolongs p73 half-life. (f) p73 half-life determination. UR61 cells transfected with HA-TAp73a were split into two and each
cultured with either Dex (þDex) or DMSO (Dex), after 6 h both cultures were treated with 20 mg/ml of cycloheximide (CHX). Total cell lysates were used to detect p73 levels
by immunoblotting. Densitometric analysis was performed to quantify protein expression and each sample value was normalized by its correspondent loading control. The
graph shows the quantification of the remaining TAp73a
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cotransfected Ras and TA-p73a and asked whether Ras could
also upregulate ectopic p73. In the presence of ectopic Ras,
cotransfected TA-p73a levels analyzed with either anti-p73 or
anti-HA antibodies were higher (Figure 1d). In contrast,
expression of H-RasV12 did not affect the levels of GFP,
which was used to normalize the transfection efficiency. The
same results were obtained in SH-SY5Y cells (Figure 1e), a
human neuroblastoma cell line where oncogenic Ras results
in neuronal-like differentiation.12 These data indicate that Ras
overexpression increases p73 steady-state levels in rat and
human cells.
To quantify Ras-mediated stabilization of p73, we deter-
mined the p73 half-life in UR61 cells in the presence and
absence of Ras. Cells transfected with TAp73a were
incubated with or without Dex and 12 h later, treated with
cycloheximide (CHX). As shown in Figure 1f, in absence of
activated Ras (Dex), transiently expressed p73 had a half-
life of about 6 h, whereas with Dex, p73 levels were
maintained even at 12 h after CHX treatment (Figure 1f).
Oncogenic Ras enhances TAp73 activity. We observed
that in the presence of Ras, p73 induction of p21WAF1, a p53/
p73 transcriptional target, was stronger (Figure 1e), whereas
endogenous p53 levels were not affected by Ras expression
(Figure 1e). Therefore, we sought to investigate whether
Ras-mediated p73 stabilization resulted in increased p73
transactivation. Promoter reporter assays were performed in
UR61 cells with constructs containing the luciferase gene
driven by multiple p53 consensus binding sites (PG13
promoter) (Figure 2a and b) or by the full-length p21WAF1
promoter (Figure 2c). In UR61 cells, TAp73a consistently
activated the PG13 promoter weakly, whereas cotransfection
of TAp73 and H-RasV12 dramatically enhanced TAp73a
transactivation (Figure 2a). Similar results were obtained in
the inducible system (Supplementary Figure 2a). It is worth
mentioning that neither ectopic expression of p53 nor p73
elicited a strong transcriptional response of the PG13 or
p21WAF1 promoters in UR61 cells. However, ectopic
expression of H-RasV12 (Figure 2a), or induced N-RasK61
(Supplementary Figure 2a), resulted in increased promoter
activity. Previous reports,13 as well as our own data
(Supplementary Figure 1), have shown that endogenous
p53 levels do not increase upon Ras transfection in UR61
cells. Consequently, Ras-induced reporter activation could
be accounted by the accumulation of endogenous p73, even
though p53 involvement cannot be completely ruled out in
this system.
To address whether Ras could modulate TAp73 transacti-
vation in the absence of p53, we used human HCT116p53/
Figure 2 Oncogenic Ras enhances p73 activity. Cotransfection of activated
Ras with TAp73a resulted in enhanced p73 transactivation function in UR61 (a and
c) or HCT116p53/ cells (b). Transcriptional analyses were performed in cells
transiently transfected with the PG13-luciferase reporter promoter (a and b) or the
p21WAF1 full-length promoter (p21-FL-Luc) (c), together with the indicated
expression vectors. (b) Transfected cells were treated with 20 mM of U0126 or
DMSO (NT). Luciferase activity was normalized by the Renilla activity of the same
lysate. The data are mean values from at least three independent experiments.
Error bars indicate S.E. (*Po0.05 **Po0.005)
Functional interaction between p73 and Ras
B Fernandez-Garcia et al
256
Cell Death and Differentiation
cells, which harbor a constitutively active K-Ras mutation and
lack p53.14,15 In these cells, TAp73a overexpression elicited
a strong upregulation of the PG13-luciferase activity
(Figure 2b). Conversely, TAp73a292, a DNA-binding incom-
petent mutant, did not activate the promoter. Blockage of Ras
signaling pathway with a MEK inhibitor, U0126 (10 mM),
decreased significantly, but not completely, TAp73a-mediated
activation of the reporter (Figure 2b). Consistently, Dex-
enhanced TAp73a activation of the PG13 promoter was
dramatically inhibited upon U0126 treatment (Supplementary
Figure 2a).
p21WAF1 plays an important role in Ras-induced cell cycle
arrest.16 However, p53-independent pathways for Ras-
mediated growth arrest and p21WAF1 upregulation have been
reported.16 Therefore, we investigated whether activated Ras
could modulate TAp73 upregulation of the p21WAF1 promoter
in the UR61 system. In these cells, expression of TAp73a,
p53wt or H-RasV12 weakly induced the p21WAF1 promoter
(2 induction) (Figure 2c), which parallel their effect on the
PG13 promoter (Figure 2a). Nevertheless, coexpression of H-
RasV12 and TAp73 resulted in a robust transactivation of this
promoter (6 induction, Figure 2c). This synergistic effect
seems to be specific for TAp73, as cotransfection of H-
RasV12 with p53wt resulted in a mere additive induction of
activity (4 induction, Figure 2c).
We used the HCT116p53/ cells to address whether Ras
modulation of TAp73-mediated p21WAF1 transactivation was
p53 independent. As expected, the strong upregulation of the
p21WAF1 promoter elicited by TAp73a was affected signifi-
cantly by treatment with U0126 (Figure 3a). Furthermore, the
levels of endogenous p21WAF1 induced by ectopic expression
of TAp73a, decreased drastically in cells treated with U0126
(Figure 3b). It is worth mentioning that we could observe a
reduction of ectopically expressed p73 as a consequence of
MEK inhibition on shorter film exposure (Figure 3b); suggest-
ing again that Ras/MEK pathway stabilizes p73.
As MEK activation is strictly dependent on Ras, we wanted
to explore the consequence of the knockdown expression of
K-Ras by shRNA over TAp73-mediated p21WAF1 transactiva-
tion. Repression of K-Ras expression resulted in an attenua-
tion on the p21 levels induced by transfected TAp73a
(Figure 3c). Furthermore, the levels of ectopically expressed
TAp73 decreased in the absence of K-Ras (Figure 3c). These
results substantiate the role of Ras signaling in TAp73 protein
stability and function.
p73 activates the MAP kinase signaling pathway and
synergizes with Ras in this activation. Unexpectedly, we
observed that ectopic expression of TAp73 resulted in
Figure 3 Ras functional inhibition results in an attenuation of the p21WAF1
expression induced by p73 in absence of p53. Inhibition of Ras signaling through the
MAPK cascade by treatment with the MEK inhibitor U0126 leads to an abatement of
p73 transcriptional function. (a) Transcriptional analysis of the p21-FL-Luc promoter
in HCT116p53/ cells transiently transfected with the indicated expression
vectors. Transfected cells were treated with 20 mM of U0126 or DMSO (NT).
Luciferase activity was normalized by the Renilla activity of the same lysate. The
data are mean values from at least three independent experiments. Error bars
indicate S.E. (b) HCT116 p53/ cells were transfected with either empty vector or
TAp73a expression plasmid and treated with DMSO (NT) or U0126 (20 mM).
Immunoblot analysis of p73, p21WAF1 and pp-ERK were performed as before with
specific antibodies. K-Ras shRNA inhibits p21WAF1 induction by TAp73a
overexpression. (c) HCT116 p53/ cells either with shRNA against K-Ras or
scrambled shRNA (scr-RNA) were, 18 h later, transiently transfected with empty
vector or TAp73a expression plasmid. Immunoblot analysis of p73, p21WAF1 K-Ras
and pp-ERK were performed 24 h later as before. Total ERK expression was used
as loading control. Expression of endogenous K-ras and GAPDH were analyzed by
semiquantitative RT-PCR
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increased endogenous levels of phosphorylated-ERK (pp-
ERK) (Figure 3b), suggesting that TAp73 could activate the
MAPK cascade by itself. To address this question, we
studied the ability of p73 to activate downstream targets of
Ras activation in UR61 cells.
First, we analyzed the ability of p73 to activate Elk1, a
phosphorylation substrate of activated ERK. UR61 cells were
cotransfected with a Gal4-reporter plasmid (Gal4-Luc) and an
expression vector for the chimeric Gal4-DNA-binding domain
fused to the transactivation Elk1 domain (Elk1-Gal4),17
together with different p73 plasmids. TAp73a and TAp73b
significantly activated the MAP kinase reporter (Figure 4a).
This activation was reproduced in SH-SY5Y and NTera2 cells
(Supplementary Figure 3a and b). Both human cell lines are
able of terminal differentiation along the neuronal pathway
upon retinoic acid treatment.18,19 Thus, the p73-mediated
enhancement of MAPK activity was consistent in the
neuronal-derived cell lines.
To further address at which point p73 is activating this
cascade, we studied the effect of TAp73 on endogenous ERK
activation. As shown in Figure 4b, ectopic expression of
TAp73a resulted in increased pp-ERK, but it did not alter total
ERK expression.
Considering that differentiation of PC12 cells by oncogenic
Ras is accompanied by increased AP-1 (activator protein-1)
activity,20 and that the signaling pathway from Ras to AP-1
appears to be mediated through the Raf/MEK/ERK module,21
we decided to test whether overexpression of TAp73 could
affect AP-1 activity in this model. Expression of TAp73a and
TAp73b resulted in a robust stimulation of AP-1 activity
(Figure 4c), confirming that TAp73 activation of the MAPK
cascade could result in activation of Ras targets relevant to its
cellular outcome.
Like UR61 cells, the human SH-SY5Y and NTera2 cells
contain a wild-type p53 gene22–24 To determine whether p73
activation of the MAPK cascade was independent of p53
status, we performed a similar experiment in SaOs-2, a
p53 null human osteosarcoma cell line with no oncogenic
Ras,25 and in HCT116p53/ cells. Ectopic expression of
TAp73a and b induced Elk1 activity (Figure 5a and b) in both
cell lines.
In SaOs-2 cells, p73-mediated induction of Elk1 activity was
weak, but nevertheless similar to the activation mediated by
H-RasV12 in these cells (Figure 5a). On the other hand,
TAp73 was capable of inducing a vigorous MAPK activation in
HCT116p53/ cells, which contain mutated Ras (Figures 3b
and 5b). This result led us to hypothesize that TAp73
activation of the MAPK cascade was stronger in the presence
of oncogenic Ras. Furthermore, treatment of HCT116p53/
cells with U0126, or suppression of K-Ras expression by
shRNA, abolished this activation (Figures 3b and c and 5b),
confirming the cooperation between p73 and Ras.
Figure 4 TA-p73 activates the MAP kinase signaling pathway. (a) MAP kinase
reporter assay was performed transfecting the Elk1-Gal4/Gal4-Luc reporter system
together with the indicated p73 expression vectors in UR61 cells. (b) TAp73a increases
ERK activation. UR61 cells were transiently transfected with the indicated expression
vectors and analysis of phosphorylated ERK protein levels (pp-ERK) was performed by
Western blot assay. Expression of transfected Tap73a and H-RasV12 were analyzed with
specific antibodies (ER15 and Ab-4 respectively). Total ERK expression was used as
loading control. (c) AP-1 activation assay was performed in UR61 cells transiently
transfected with both the AP-1 reporter plasmid (73Col1-AP1-Luc) and the indicated
plasmids. Luciferase activity was measure and normalized as before. The data represent
the mean of at least three experiments. Error bars indicate S.E. (*Po0.05, **Po0.005)
Figure 5 TAp73a synergizes with oncogenic Ras in the activation of MAP kinase signaling cascade independently of p53. (a–e) MAP kinase reporter assay were
performed as before in either the p53 null cells SaOs-2 (a), the HCT116p53/ cells (b) or in UR61 cells (c–e) with the indicated expression plasmids. (b) Transfected cells
were treated with the MEK inhibitor U0126 (20 mM) or DMSO as control (NT). Expression of transfected TA-p73a and pp-ERK were analyzed by Western blot as described
before. (d) Transfected cells were cultured in the presence of Dex (þDex) to induce N-Ras expression, or the vehicle (NT). Luciferase activity was measured and normalized
as before. The data represent the mean of at least three experiments (7S.E. *Po0.05). (d–e) Expression of endogenous (TA-p73a) and transfected p73 (HA-TAp73a) were
analyzed by Western blot with the ER15 antibody. The levels of transfected H-RasV12 (d–e), K-RasV12, N-RasE12 (e) as well as the inducible N-RasK61 (d) were analyzed
with anti-pan Ras antibody. Total ERK (d) or GFP (e) expression were used as loading control
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To further investigate this cooperation, we studied Elk1
activation in UR61 cells. Consistent with our previous results,
TAp73a and TAp73b by themselves induced a moderate
activation of Elk1 when compared with H-RasV12, whereas
p53wt had no effect. However, TAp73a cotransfected with
Ras and to a lesser extent TAp73b, but not p53wt, had a more
than additive effect on Elk1 activation (Figure 5c). The
attenuation of Ras-induced Elk activation observed in the
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presence of p53 is consistent with a recent report where wild-
type p53 directly interfered with Ras/MAPK cascade.26 We
tested whether TAp73a could also enhance the signal
triggered by the inducible N-RasK61. Ras induction resulted
in a mild activation of Elk, similar to the activation triggered by
ectopic TAp73a alone (Figure 5d). However, treatment with
Dex produced a dramatic increase in TAp73a-induced
Elk activity (Figure 5d), confirming the synergistic effect
between TAp73 and Ras in the activation of the MAPK
cascade. In this experiment, we can observe that the levels of
endogenous (TA-p73a) as well as ectopic (HA-TA-p73a) p73
were augmented with Dex treatment (Figure 5d, insert),
confirming our previous observation of Ras-mediated p73
stabilization.
Although the role of the three members of the Ras family
(H-Ras, N-Ras and K-Ras) during embryonic development
seems to be unique,27 activated versions of all of them can
induce neuronal differentiation in in vitro.16 We asked whether
all the Ras isoforms could cooperate with p73 and observed
that the synergistic effect was common to the three Ras genes
(Figure 5e).
This cooperative effect between TAp73 and Ras is neither
dependent of p53 status, as it is reproducible in SaOs-2 cells
(Figure 5a), nor cell specific as it is consistent in human SH-SY5Y
and NTera2 cells, and in mouse embryonic fibroblast (Supple-
mentary Figure 3a and 3b and data not shown). However,
we failed to detect a cooperative effect in the lung carcinoma
cell line H1299, where ectopic expression of oncogenic Ras did
not activate this reporter system (data not shown).
Functional inactivation of p73 attenuates Ras activation
of ERK. To define the role of p73 function in Ras activation
of the MAPK cascade, siRNA oligonucleotides homologous
to 5-prime unique TAp73 sequences,28 missing in DNp73,
were used to inhibit the accumulation of p73. In
HCT116p53/ cells, transfection of p73 siRNA, but not
scrambled siRNA, led to decreased endogenous TAp73
without affecting the levels of total ERK (Figure 6a). TAp73
siRNA, but not control siRNAs, attenuated the high
endogenous levels of pp-ERK (Figure 6a and b, *Po0.05)
as well as endogenous p21 (Figure 6a), confirming our
hypothesis that p73 function contributes to Ras activation of
the MAPK cascade.
We utilized the widely used dominant-negative p73 (p73-
DD) mutant29 to functionally inactivate endogenous p73 in
UR61 cells. As in vitro translated p73-DD and human p63
proteins are capable of binding,29 we analyzed whether p73-
DD could bind the endogenous rat p63. Immunoprecipitation
studies with an antibody (GC15) specific against p73-DDb30
failed to show interaction between p73-DD and endogenous
rat p63, in conditions where p73-DD and endogenous TAp73a
complexes were detected (Figure 6c). Neither did we detect
interaction between p73-DD and p63 using an antibody
against p63 (Figure 6c). These data validate p73-DD as
suitable reagents to specifically inactivate p73 in UR61 cells.
We then analyzed the effect of p73 inhibition in Ras-induced
activation of the Elk1-reporter system. As shown in Figure 6d,
p73-DDwt, but not the inactive dominant-negative p73 (p73-
DD-L371P), decreases up to 40% (*Po0.05) Ras-mediated
activation. The apparent Elk1 activation elicited by p73-DD-
L371P was not statistically significant (P40.5). Similar results
were obtained in HCT116p53/ cells, where p73-DDwt, but
not the mutant p73-DD-L371P (data not shown) reduced the
levels of Elk1 activation. Taken together, these data indicate
that functional inhibition of TAp73 results in an attenuation of
endogenous Ras-mediated MAPK cascade activation.
p73 function is necessary for Ras sustained ERK
activation and the subsequent differentiation. As noted
in the Introduction, both p73 and Ras have been involved in
cell differentiation in several models.3,16 In UR61 cells,
induction of the activated N-Ras gene results in growth arrest
and neuronal-like differentiation.11 Following 24 h of
treatment with Dex, 70% of the UR61 cells showed the
morphological changes of neuronal-like differentiation
(Figure 7a). As in PC12 cells,6 this process is dependent
on the Ras/Raf/MEK/ERK activation, as the MEK inhibitor
U0126 completely blocked it, whereas treatment with p38
(SB303580 and SB202190), or PI(3)K (LY294200) inhibitors
did not affect the process (Figure 7b). In addition, p73
expression profile correlates with the kinetics of Ras-induced
differentiation in these cells (Figure 1a).
To determine the role of p73 in Ras-mediated differentiation,
we utilized p73 and p53 dominant-negative mutants. As shown
in Figure 7c, p73-DDwt, but not a dominant-negative p53 (p53-
DD), resulted in a significant decrease (*Po0.05) in the
number of differentiated cells compared with cells transfected
with GFP alone. To confirm this result, UR61 cells were
infected with recombinant bicistronic adenoviruses encoding
GFP-p73-DDwt or the inactive GFP-p73-DD-L371P,28 and
treated with Dex. Infection with the inactive mutant failed to
inhibit the differentiation process, whereas 90% of cells infected
with p73-DDwt lacked any of the morphological changes
associated with neuronal-like differentiation (Figure 7d top and
middle panels, respectively). Confocal microscopy analysis
showed that the GFP-p73-DDwt-infected cells remained
viable, with a globular morphology and cytoplasmic blebs
similar to those of undifferentiated cells, whereas the surround-
ing noninfected cells presented a neuronal-like phenotype with
neurite extensions that finished in growth cones and lacked
blebs (Figure 7d). Overall, these data demonstrate that p73
function plays a critical role in Ras-induced differentiation.
Sustained ERK activation is necessary for Ras-induced
differentiation in PC126 and UR61 cells (Figure 7b). Thus, we
decided to elucidate the impact of p73 inactivation in Ras-
induced ERK activation in our system. In vector-infected cells,
pp-ERK was detected as earlier as 6 h and maintained up to
36 h (Figure 7e and f). Consistent with our previous results,
pp-ERK was detected in Ad-p73-DDwt-infected cells, but this
phosphorylation was not sustained and disappeared after 12 h
of treatment, despite the continuous treatment with Dex
(Figure 7e and f). The magnitude of N-RasK61 protein
expression was not affected by the adenoviral infections, so
the effect on ERK activation was not due to lack of activated
Ras protein (Figure 7f). Altogether these data prove that
functional inactivation of p73 modifies the cellular outcome of
Ras activation, resulting in transient, rather than sustained,
Ras-mediated ERK activation, and in the subsequent inhibi-
tion of differentiation.
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Discussion
Ras has the capacity to elicit cell cycle arrest and, in primary
cells, to induce replicative senescence.5,16 The accumulation
and activation of tumor suppressor genes, like p53, is part
of the fail-safe mechanism of a normal cell against the
uncontrolled proliferation elicited by oncogenic stimuli.8
Although the crosstalk between Ras signaling pathway and
p53 activation is well established, it remains unclear how the
Ras/MEK/ERK pathway induces growth arrest in the absence
of p53. Our studies offer one possible mechanism of Ras
cellular outcome independent of p53. Our data show that Ras
constitutive activation leads to the stabilization of p73. In
addition, TAp73 can induce a sustained activation of the MAP
cascade and synergize with Ras modulating the strength of
the response. We also present evidence that p73 function
plays a decisive role in Ras-mediated neuronal differentiation.
Constitutive active Ras induces p73 accumulation and
enhances p73 activity. Ras oncogenic activation leads to
the stimulation of p53 activity.8 We report here a similar
scenario, where constitutive Ras activation leads to
stabilization of p73 and thereby augments p73
transcriptional activity. This effect is dependent on the
cellular context, which is consistent with the tissue specificity
of p73 tumor suppression function.2 For example, in H1299
cells, activated Ras fails to stabilize p73 and to enhance its
activity (B Fernandez-Garcia, unpublished results).
Figure 6 Functional inactivation of p73 attenuates Ras-induced ERK activation. p73 siRNA decreases endogenous p73 levels. (a) HCT116p53/ cells were transfected
with siRNA against p73 or scrambled control and 72 h later p73, p21WAF1 and pp-ERK were performed as before. Total ERK expression was used as loading control. Genetic
disruption of p73 attenuates Ras-induced MAPK cascade activation in the presence or absence of p53. (b) HCT116p53/ cells transfected with siRNA against p73,
scrambled control or with annealing buffer only (mock) were transiently transfected 48 h later with the MAP kinase reporter plasmids to measure the endogenous levels of
activated ERK. (c) Validation of the p73 dominant-negative mutants (p73DD) specificity in rat UR61 cells. Cellular lysates from UR61 cells transfected with human p73-DDbwt
were immunoprecipitated with specific antibodies: anti-p73 (GC15), anti-p63 (4A4) or control antibody (anti-TAg 419). Cell lysate with ectopically expressed Tap73a was used
as marker. Protein complexes were analyzed by Western blot against p63 (4A4) or p73 (ER15). (d) MAP kinase reporter assay was performed cotransfecting the indicated
vectors together with the reporter plasmids. The p73-DDwt expression vector harbors a p73-DD, whereas the p73-DD-L371P harbors an inactive point mutant. The values
were compared with the value scored by transfected oncogenic H-RasV12. Luciferase activity was measured and normalized as before. The data represent the mean of at
least three experiments (7S.E. *Po0.5)
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TAp73 expression levels are usually kept extremely low
under normal conditions, making stabilization of p73 a critical
control mechanism for its effects on the cell. Several lines of
evidence indicate that stress-induced post-translational mod-
ifications of p73 such as phosphorylation and acetylation lead
to a marked extension of its half-life. Furthermore, p73 stability
is regulated, at least in part, by a proteasome-dependent
degradation pathway.4,31 We have failed to detect p73
acetylation in the presence of activated Ras in our system,
suggesting that some of the other pathways are responsible for
the stabilization (B Fernandez-Garcia, unpublished results).
p73 can modulate oncogenic Ras activation of the MAP
kinase signaling cascade. Our results indicate that TAp73
Figure 7 p73 function is necessary for Ras sustained ERK activation and the subsequent differentiation. Activation of the MAP kinase pathway is required for Ras-induced
neuronal phenotype in UR61 cells. (a) Photomicrographs of UR61 cells incubated with vehicle control (DMSO) or Dex (Dex, 200 nM) 24 h after treatment. Although control-
treated cells presented a globular morphology, the cells with Dex treatment showed a neuronal-like phenotype with numerous neurite extensions with growth cones. (b) UR61
cells were treated for 24 h with either Dex alone (Dex) or Dex plus one of the following inhibitors (10 mM U0126, 1 and 10 or 30mM of SB203580 or SB202190, respectively,
and 2.5 and 5mM of LY294220). The number of differentiated cells was scored by counting the number of cells with neurite extensions with a length at least two cell body
diameters. The number of cells differentiated with Dex alone was considered 100%. Each experiment was performed at least three times. (7S.E. **Po0.005). p73 function is
necessary for neuronal differentiation. (c) UR61 cells were transfected with GFP vector alone or together with expression plasmids containing either p73-DDwt or a p53
dominant negative (p53-DD). After 24 h of treatment, the percentage of GFP-positive cells that presented neurite extension was scored for each transfection. All values were
compared with the value scored by the GFP-alone transfected cells. Each experiment was performed at least three times with similar results. (7S.E. *Po0.05). (d) UR61
cells infected with a bicistronic adenoviral vector encoding GFP and p73-DD-L371P (top) or GFP and p73-DDwt (middle and bottom) were treated with Dex for 48 h and
photomicrographs were taken by phase contrast and fluorescence microscopy (top and middle) or by confocal microscopy (bottom). For confocal analysis, the cells were
stained with actin-binding phalloidin-TRITC (Ph) to visualize the cytoskeleton. p73 function is required for Ras sustained ERK activation during the differentiation process. (e
and f) The expression profile of ERK activation during Ras-induced differentiation in UR61 cells was analyzed by Western blot. Cells were infected with a bicistronic adenoviral
vector encoding GFP alone or GFP and p73-DDwt and treated with Dex. At the indicated times, cell lysates were prepared and analyzed as before
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synergizes with oncogenic Ras in the activation of the MAPK
cascade leading to increased ERK activation. It has been
proposed that oncogenic activation of the MAPK pathway in
MEFs modifies the outcome of p53 activation32, on the other
hand, the functional cooperation between p53 and TAp73
has been established.2,28,29 Therefore, a possible
consequence of this synergy is that p73-mediated
enhancement of ERK signaling results in further activation
of p53, establishing cooperation between TAp73 activation
and p53 function in the cellular response to oncogenic Ras.
This possibility is currently under investigation in our
laboratory.
The transcriptional function of p73 is required to activate the
MAPK cascade. However, the cooperation with oncogenic
Ras, seems to involve additional p73 interactions. The fact
that TAp73b shows a diminished ability to cooperate with Ras
suggests that TAp73a superactivation of the MAPK cascade
does not depend only on TAp73 transcriptional functions, but
also engages unknown interaction/s within the C-terminal
region. As DNp73a shares with TAp73a the C-terminus
region, it remains to be determined whether it also cooperates
with oncogenic Ras in the activation of the MAPK cascade,
and the cellular outcome of this cooperation. This scenario will
be in accordance with a previous report that indicates that
DNp73 cooperates with oncogenic Ras in cellular transforma-
tion.3 It remains unknown whether the mechanism of this
cooperation relies on the ability of p73 to synergize with Ras
signaling, or if it is only a reflection of DNp73 transdominant
inhibition over p53.
Our data demonstrate that p73 acts upstream of MEK
activation, but the precise point of the Ras-MEK cascade at
which p73 is acting, is still unknown.
p73 function plays a critical role in Ras-mediated
differentiation. Although Ras activation in cell lines exerts
multiple effects, one of the most prevalent effects of Ras is to
promote differentiation.16 The hypothesis proposed to
explain this paradox relays in the existence of cell-specific
modulators of the Ras signaling pathways. Here, we show
that TAp73 can modulate the strength of the Ras-mediated
MAPK cascade activation, as functional inactivation of p73
results in transient rather than sustained Ras-mediated ERK
activation. Furthermore, lack of p73 function blocks Ras-
induced differentiation in UR61 cells. In the light of these
data, it is tempting to hypothesize that p73 can function as a
contextual modulator of the cellular response to Ras
activation. As sustained ERK activation is necessary for
Ras-induced differentiation in UR61 cells, it is conceivable
that p73 contributes to Ras-mediated differentiation by
increasing the strength and duration of signaling by the
Ras-MAPK cascade. It will be important to address whether
p73 can mediate other Ras-induced cellular outcomes.
Materials and Methods
Cell lines, culture conditions and transfections. Rat pheochromo-
cytoma cells UR61, human colorectal carcinoma cells HCT116 p53/,
neuroblastoma cell line SH-SY5Y (provided by Dr. A Silva, Centro de
Investigaciones Biolo´gicas, Madrid, Spain) and human osteosarcoma cells SaOs-
2 were maintained in DMEM medium supplemented with 10% fetal bovine serum,
200 mM, L-glutamine, in a 5% CO2 humidified atmosphere at 371C. The NTera-2
(NT-2) cells (provided by Dr. D Pleasure, University of Pennsylvania, Philadelphia,
USA) were maintained in DMEM with 10% fetal bovine serum, 200 mM L-glutamine,
in a 10% CO2 humidified atmosphere at 371C. All cell culture products were
purchased from Sigma.
For protein analysis, the cells were transfected with the indicated expression
vectors using jetPEITM (Polyplus Transfection) following the manufacturer’s fast
protocol. Cells were transfected with 4 mg of the indicated plasmid together with
1 mg pBB14 (Us9-GFP) and 10ml of JetPEI in 150 mM NaCl. Twenty-four hours
later, cells were harvested and cellular extracts prepared as described below. In
some experiments, the cells were treated 6 h after transfection with 10 mM U0126 or
vehicle (DMSO) and processed for Western blot analysis 24 h later.
To analyze the effect of p73-DD mutants, UR61 cells were transfected with
1.8mg of total DNA (0.2mg of pcDNA3-GFP and 1.2mg of vector (1 : 6), or 0.2mg of
GFP together with 1.2mg (1 : 6) of one of the dominant-negative constructs:
pcDNA3-p73bDD, pcDNA3-p73bL371P or pcDNA3-p53DD). The transfections
were performed with Lipofectamine Plus Reagent (Invitrogen) according to the
manufacturer’s protocol. Twenty-four hours after transfection, cells were treated
with 200 nM Dex for 24 h and analyzed for neurite outgrowth as described below.
Neurite outgrowth analysis. UR61 cells were seeded at 60% confluence
and next day treated with 200 nM Dex (Sigma). To analyze the effect of the different
inhibitors, cells were treated with Dex together with one of various concentrations of
the MAPK inhibitors (10 mM of U0126 (Calbiochem), 2.5 or 5mM of LY294200
(Calbiochem), 30mM of SB202190 (Calbiochem) or 1 or 10mM of SB203580
(Sigma)). After 24–48 h of treatment, the differentiated cells were quantified using
an inverted microscope (Nikon Eclipse TE300) by counting the cells with
prolongations at least 2 times the diameter of soma. For each experiment, four
quadrants with at least 100 cells were counted.
p73-DD mutants were transfected and treated as described above, and the GFP-
positive cells that presented neurite extensions were counted, considering the
number of differentiated cells transfected with pcDNA3-GFP alone as 100%.
Adenoviral plasmids and infections. The generation of the bicistronic
adenoviral vectors pAd GFP-T7-p73DDwt, pAd GFP-T7-p73DD-L371P and pAd
GFP-T7-vector has been described earlier.28 As described before, tissue culture
supernatants of 293A cells transfected with these plasmids were harvested and viral
particles were purified by cesium chloride centrifugation. Equivalent amounts of
infection particles were used to infect UR61 cells. Twenty-four hours after infection,
cells were treated with Dex as described above, and 24–36 h later the neurite
outgrowth of living cells was analyzed by capturing digital images on an inverted
epifluorescence microscope (Nikon Eclipse TE300) or by laser confocal microscopy
(see below). For protein expression analysis during the differentiation process of
UR61, cells were plated, next day infected overnight with the adenoviral
constructions and 24 h later treated with 200 nM Dex. Cellular extracts were
prepared (see below) at the indicated times.
Immunostaining and confocal analysis. Cells were seeded on poly-D-
lysine (Becton-Dickinson)-treated coverslips, 24 h later they were infected as
described above and then treated with 200 nM Dex for another 24 h. Cells were
fixed in 3% paraformaldehyde/2% sucrose, permeabilized with 0.2% Triton X-100 in
PBS and incubated in Phalloidin-TRITC (Sigma) for 30 min.
Coverslips were mounted on Vectashield Mounting Medium (Vector Labs) and
analyzed by confocal microscopy (Radiance 2000, Bio-Rad).
Western blot analysis. Cells were lysed in EBC lysis buffer (50 mM Tris pH 8,
120 mM NaCl, 0.5% NP-40) supplemented with protease inhibitors (Aprotinin,
Leupeptin 20mg/ml, sodium orthovanadate 1 mM and PMSF 0.1 mg/ml, all from
Sigma). Immunoblots were performed as described previously33 and incubated
overnight at 41C in the following primary antibodies: mouse anti-p73 1 : 500 (Ab-2
and Ab-4 Oncogene), anti-p63 1 : 1000 (4A4 Becton-Dickinson), anti-p53 1 : 500
(Ab1 Oncogene), anti-pan-Ras 1 : 500 (Ab-4 Oncogene), anti-RasV12 1 : 500 (Ab-1
Calbiochem), anti-ppERK 1 : 10 000 (E-4 Santa Cruz), anti-ERK 1 : 10 000 (C-14
Santa Cruz), anti-p21-WAF 1 : 1000 (C-19 Santa Cruz), anti-HA 1 : 500 (Y11 Santa
Cruz), anti-Kras 1 : 500 (F234 Santa Cruz) and anti-GFP 1 : 500 (FL Santa Cruz).
Membranes were incubated with the appropriated HRP-coupled secondary
antibodies (Pierce) and the enhanced chemiluminiscence was detected with
Super Signal West-Pico Chemiluminiscent Substrate from Pierce.
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Immunoprecipitation. For the analysis of p73 expression during the
differentiation in UR61 cells, p73 immunoprecipitation was performed as
described previously.33 Cells were seeded and treated with Dex 200 nM at
indicated times. Cells were lysed in EBC lysis buffer, incubated for 1 h with ER15
supernatant antibody in NET-N buffer and incubated for 30 min with protein
A-sepharose. Western blot analysis was performed as described before.
The interactions between p73-DD and endogenous rat p73 or p63 were studied
in UR61 cells stably transfected with p73DDb. The cells were treated with Dex
(200 nM) and 12 h later cell lysates were prepared as described. Equal amounts of
protein were incubated with specific antibodies (Anti-TAg (419 mAb) as control anti-
p73b (GC15) or anti-p63 (4A4)). Protein complexes were analyzed by Western blot
as described above.
RNA interference analysis. The knockdown of Kras was performed by
shRNA. The shRNA vectors were constructed by cloning the following oligos in the
pSiren-ZsGreen vector following manufacturer’s instructions (BD Biosiences).
K-Ras general-up: GATCCGCAGGCTCAGGAGTTAGCAATTCAAGAGATTGC
TAACTCCTGAGCCTGCTTTTTTGCTAGCG;
K-Ras general 4-lo: AATTCGCTAGCAAAAAAGCAGGCTCAGGAGTTAGCA
ATCTCTTGAATTGCTAACTCCTGAGCCTGCG;
K-Ras scrambled-up: AGCTTGGCTTAGGCTCGATGAGGCTTTCAAGAGAAG
CCTCATCGAGCCTAAGCCTTTTTTGCTAGCA;
K-Ras scrambled-lo: GATCTGCTAGCAAAAAAGGCTTAGGCTCGATGAGGCT
TCTCTTGAAAGCCTCATCGAGCCTAAGCCA.
HCT 116p53/ cells were transfected with 8 mg of pSiren-ZsGreen-scrambled
or 8 mg of pSiren-ZsGreen-K-Ras general using 16 mg of JetPEI. After 24 h, cells
were split and transfected with 8mg of pcDNA3 or pcDNA3-HA-TAp73a plasmids
and 16mg of JetPEI. Twenty-four hours later (48 h after pSiren transfection), cell
lysates were obtained and analyzed as described above.
The knockdown of p73 was performed using anti-p73 siRNA oligos provided by
Dr. M Irwin (Cancer Research and Developmental Biology, Toronto University, ON,
Canada) and previously described.28 HCT116p53/ cells were transfected with
siRNA at approximately 20–30% confluence using Oligofectamine (Invitrogen). For
Western blot analysis, proteins were recovered 72 h later as described before. For
luciferase reporter analysis, cells were transfected 48 h after oligofection with 1 mg
of Elk1-Gal4, 1 mg of Gal4-Luc and 0.5mg of pRL-Null. Twenty-four hours later, cell
extracts were prepared for luciferase analysis as described below.
In vitro translation. In vitro translation was performed with the TNT translation
system (Promega) according to the manufacturer’s protocol.
Luciferase reporter assay. Cells (2 106) were electroporated at 260 V
and 1 mF (Bio-Rad Gene Pulser) in serum-free medium with one of the following
reporters: p73-P1-Luc (1ug), p21-FL-Luc (4mg), -73Col-AP1-Luc (4 mg), plus 0.5–
2mg pRLNull (Renilla luciferase) and 3–9mg of the indicated expression vectors.
The luciferase reporter p21-FL-Luc was described previously. We used a 73 bp
fragment of the collagenase-I promoter (73Col1-AP1-Luc) containing the AP-1
responsive site as the AP-1 reporter gene34 that was provided by Dr. A Mun˜oz
(Instituto de Investigaciones Biome´dicas, Madrid, Spain).
For PG13-Luc reporter activity (provided by Dr. A Silva, Centro de
Investigaciones Biolo´gicas, Madrid, Spain), 1 106 UR61 cells were transfected
with 0.5mg of the reporter, 0.5mg pRLNull and different amounts (0.5–1mg) of the
expression vectors using jetPEITM following the manufacturer’s fast protocol. When
indicated, cells were treated with Dex (200 nM, Sigma) and the MAPK inhibitor
(10mM U0126) 6 h after transfection.
Cellular extracts were prepared (Passive Lysis Buffer, Promega) 16 h after
electroporation or 24 h in the case of jetPEI transfection, and the luciferase activity
was determined using the Dual-Luciferase Reporter Assay System (Promega)
following the manufacturer’s instructions in a Berthold’s luminometer and
normalized by the values of the Renilla luciferase.
MAP kinase reporter assay. Cells (2 106) were electroporated at 260 V
and 1 mF (Bio-Rad Gene Pulser) in serum-free medium with 4 mg of pSG424-Gal4-
Elk1 (CMV promoter-driven GAL4-DNA binding domain-Elk fusion protein) and 4 mg
of pSG5Gal4-Luc (GAL4 promoter-driven luciferase) plus 2 mg pRLNull (Renilla
luciferase) and 3–9 mg of DNA of the indicated expression vectors. The MAP kinase
reporter system was provided by Dr. Cobb, Southwestern Medical Center, TX, USA.
After 16 h of the electroporation, cells were lysed and the luciferase activity was
determined as described above.
Reverse transcription-polymerase chain reaction. To analyze Kras
knockdown in shRNA experiments, RNA was extracted with RNA-wiz reagent
(Ambion) following the manufacturer’s protocol. cDNA was prepared using the
Ready-To-Go First Strand kit (APB) according to the manufacturer’s protocol. The
primers and conditions used to amplify GAPDH were published before.35 To amplify
K-ras, the primers used were: K-ras-sense ACTTGTGGTAGTTG GAGCTGGTGGC
and K-ras-antisense GCAAATACACAAAGAAAGCCCTCCC.
In differentiation analysis, UR61 cells were treated with 200 nM Dex at indicated
times. RNA from cells and cDNA were prepared as described before. The primers
and conditions used to amplify TAp73 and DNp73 were published before.36,37 To
amplify p53 and p63, the primers used were: p53-sense GCTAAACGC
TTCGAGATGTTCCGGG and p53-antisense GCGTCTGAGTCAGGCCCCACTTT
CTTG; p63-sense GCGCTTCATAGAAACCCCATCTCATTTCTCCTGG and p63-
antisense GCGCGTTCTTTGCGCTGTCTGAGACTTG CTGCTTT.
RT-PCR products were analyzed in 3% agarose gels stained with ethidium
bromide.
Plasmids. The cDNAs from human HA-TAp73a, HA-TAp73b, TAp73a292,33
Myc-DNp73a,37 HA-p53wt38 and the dominant-negative forms p53-DD,39 pcDNA3-
T7-p73-DDbwt and pcDNA3-T7-p73-DDb-L371P were described previously.29
The expression plasmids containing the cDNAs for the oncogenic mutants H-
Ras-G12V (H-Ras V12), K-Ras-G12V (K-Ras V12), and N-Ras-G12E (N-Ras E12)
were a gift from Piero Crespo (Universidad de Cantabria, Santander, Spain).
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